Growth Hormone for the Treatment of Gastroparesis

Description

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Conditions

Gastroparesis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Low-dose Growth Hormone for the Treatment of Gastroparesis

Growth Hormone for the Treatment of Gastroparesis

Condition
Gastroparesis
Intervention / Treatment

-

Contacts and Locations

Phoenix

Mayo Clinic, Phoenix, Arizona, United States, 85054

Scottsdale

Mayo Clinic in Arizona, Scottsdale, Arizona, United States, 85259

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Symptoms \> 6 months that have not responded satisfactorily to standard treatment.
  • * For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21
  • * Known history of GH deficiency, hypothalamic or pituitary disease
  • * Diabetes
  • * Prior use of GH therapy
  • * Age-adjusted low serum IGF1
  • * Women on oral estrogen therapy6
  • * Pregnancy or nursing
  • * History of malignant solid tumors
  • * Obesity (BMI \> 30)History of coronary and thromboembolic diseases.
  • * History of sarcoidosis
  • * History of pituitary surgery
  • * History of thyroid nodules.
  • * Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.
  • * Failure to give informed consent.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Tisha Lunsford, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2027-10